XML 24 R13.htm IDEA: XBRL DOCUMENT
v3.25.2

Shareholders' Equity | 6 Months Ended
--- | ---
Jun. 30, 2025
Equity [Abstract] |
Shareholders' Equity | 7. Shareholders’ Equity (a)Authorized shares The Company is authorized to issue an unlimited number of Common Shares with no par value and an unlimited number of Preferred Shares with no par value. (b)Purchases of Equity Shares Normal Course Issuer Bid On February 12, 2025, Epsilon’s board of directors (the “Board”) authorized a new share repurchase program of up to 2,200,876 common shares, representing 10% of the current outstanding common shares of Epsilon, for an aggregate purchase price of not more than US $13.0 million. The program commenced on February 12, 2025 and ends on February 11, 2026, unless the maximum amount of common shares is purchased before then or the Board approves earlier termination. The previous share repurchase program commenced on March 19, 2024. During the year ended December 31, 2024, we repurchased 125,000 common shares and spent $627,500 at an average price of $5.00 per share (excluding commissions) under the plan. On February 12, 2025, the Board terminated and revoked authority under the program. During the six months ended June 30, 2025, no shares were repurchased under the new or previous program. (c)Equity Incentive Plan The Board adopted the 2020 Equity Incentive Plan (the “2020 Plan”) on July 22, 2020 subject to approval by Epsilon’s shareholders at Epsilon’s 2020 Annual General and Special Meeting of shareholders, which occurred on September 1, 2020 (the “Meeting”). Shareholders approved the 2020 Plan at the Meeting. The 2020 Plan provides for incentive compensation in the form of stock options, stock appreciation rights, restricted stock and stock units, performance shares and units, other stock-based awards and cash-based awards. Under the 2020 Plan, Epsilon is authorized to issue up to 2,000,000 Common Shares. Restricted Stock For the six months ended June 30, 2025, no restricted common shares were awarded to the Company’s board of directors and employees. For the year ended December 31, 2024, 300,052 restricted common shares with a weighted average grant date fair value of $5.97 were awarded to the Company’s management, employees, and board of directors. These shares vest over a three-year period, with an equal number of shares being issued per period on the anniversary of the award resolution. The vesting of the shares is contingent on the individuals’ continued employment or service. The Company determined the fair value of the granted Restricted Stock based on the market price of the common shares of the Company on the date of grant. The following table summarizes restricted stock activity for the six months ended June 30, 2025, and the year ended December 31, 2024: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Six months ended | ​ | Year ended
​ | ​ | June 30, 2025 | ​ | December 31, 2024
​ | ​ | Number of | ​ | Weighted | ​ | Weighted | ​ | Number of | ​ | Weighted | ​ | Weighted
​ | ​ | Restricted | ​ | Average | ​ | Average | ​ | Restricted | ​ | Average | ​ | Average
​ | ​ | Shares | ​ | Remaining Life | ​ | Grant Date | ​ | Shares | ​ | Remaining Life | ​ | Grant Date
​ |  | Outstanding |  | (years) |  | Fair Value |  | Outstanding |  | (years) |  | Fair Value
Balance non-vested Restricted Stock at beginning of period | ​ | 560,970 | ​ | 1.61 | ​ | $ | 5.77 | ​ | 491,536 | ​ | 1.74 | ​ | $ | 5.59
Granted | ​ | — | ​ | — | ​ | ​ | - | ​ | 300,052 | ​ | 1.92 | ​ | ​ | 5.97
Vested | ​ | (8,639) | ​ | — | ​ | ​ | 6.15 | ​ | (230,618) | ​ | — | ​ | ​ | 5.65
Balance non-vested Restricted Stock at end of period | ​ | 552,331 | ​ | 1.11 | ​ | $ | 5.77 | ​ | 560,970 | ​ | 1.61 | ​ | $ | 5.77
​ Stock compensation expense for the granted Restricted Stock is recognized over the vesting period. Stock compensation expense recognized during the three and six months ended June 30, 2025 was $385,838 and $771,676, respectively (for the three and six months ended June 30, 2024 was $313,589 and $ 635,158, respectively). As of June 30, 2025, the Company had unrecognized stock-based compensation related to these shares of $2,426,793 to be recognized over a weighted average period of 1.14 years (at December 31, 2024: $3,198,469 over 1.30 years). (d)Dividends On February 26, 2025 and June 3, 2025, the Board declared quarterly a dividend of $0.0625 per common share (annualized $0.25 per common share) totaling in aggregate an amount of approximately $2.8 million that has been paid during the six months ended June 30, 2025.

X
- References No definition available. + Details
Name: | us-gaap_EquityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContent Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContent + Details
Name: | us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration